is hoping a suite of new weight

The two big Swiss pharmaceutical companies, Roche and Novartis, will look to gain momentum in 2025 after corporate restructurings. In November, Novartis lifted its 2023-2028 sales forecast in a sign of confidence after top-selling drugs exceeded quarterly growth targets. Roche is hoping a suite of new weight-loss drug candidates will show positive results in 2025 and help cement its place in what analysts predict could be a $100 billion (CHF88 billion) market in ten years. Although it is a newcomer to obesity, Chief Executive Officer Thomas Schinecker told reporters in July he believed Roche could bring the new drugs to market “much faster” than investors expect. สล็อต เว็บตรง